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ARTICLE
Hypomorphic Recessive Variants in SUFU Impair
the Sonic Hedgehog Pathway and Cause Joubert
Syndrome with Cranio-facial and Skeletal Defects
Roberta De Mori,1,2,20 Marta Romani,3,20 Stefano D’Arrigo,4 Maha S. Zaki,5 Elisa Lorefice,1
Silvia Tardivo,1 Tommaso Biagini,6 Valentina Stanley,7 Damir Musaev,7 Joel Fluss,8 Alessia Micalizzi,1,2
Sara Nuovo,1,9 Barbara Illi,10 Luisa Chiapparini,11 Lucia Di Marcotullio,12 Mahmoud Y. Issa,5
Danila Anello,1 Antonella Casella,1 Monia Ginevrino,1,13 Autumn Sa’na Leggins,7 Susanne Roosing,14
Romina Alfonsi,12 Jessica Rosati,15 Rachel Schot,16 Grazia Maria Simonetta Mancini,16 Enrico Bertini,17
William B. Dobyns,18,19 Tommaso Mazza,6 Joseph G. Gleeson,7 and Enza Maria Valente1,13,*
The Sonic Hedgehog (SHH) pathway is a key signaling pathway orchestrating embryonic development, mainly of the CNS and limbs. In
vertebrates, SHH signaling is mediated by the primary cilium, and genetic defects affecting either SHH pathway members or ciliary
proteins cause a spectrum of developmental disorders. SUFU is the main negative regulator of the SHH pathway and is essential during
development. Indeed, Sufu knock-out is lethal in mice, and recessive pathogenic variants of this gene have never been reported in
humans. Through whole-exome sequencing in subjects with Joubert syndrome, we identified four children from two unrelated families
carrying homozygous missense variants in SUFU. The children presented congenital ataxia and cerebellar vermis hypoplasia with elon-
gated superior cerebellar peduncles (mild ‘‘molar tooth sign’’), typical cranio-facial dysmorphisms (hypertelorism, depressed nasal
bridge, frontal bossing), and postaxial polydactyly. Two siblings also showed polymicrogyria. Molecular dynamics simulation predicted
random movements of the mutated residues, with loss of the native enveloping movement of the binding site around its ligand GLI3.
Functional studies on cellular models and fibroblasts showed that both variants significantly reduced SUFU stability and its capacity to
bindGLI3 and promote its cleavage into the repressor formGLI3R. In turn, this impaired SUFU-mediated repression of the SHH pathway,
as shown by altered expression levels of several target genes. We demonstrate that germline hypomorphic variants of SUFU cause dereg-
ulation of SHH signaling, resulting in recessive developmental defects of the CNS and limbs which share features with both SHH-related
disorders and ciliopathies.
Introduction
Embryonic development is a highly complex process that
is tightly regulated by evolutionary conserved signaling
pathways. Among these, the Sonic Hedgehog (SHH)
pathway plays a central role in controlling cell patterning
and differentiation of several embryonic structures, such
as the central nervous system (CNS) and the limbs. In
the developing CNS, SHH is secreted by the notochord
and floor plate and forms a ventral to dorsal gradient
that regulates diverse essential processes such as specifica-
tion of ventral fate, proliferation, and axonal guidance.1,2
Similarly, SHH orchestrates several aspects of cerebellar
development, initially stimulating the proliferation of
cerebellar progenitors in the rhombic lip and the ventricu-
lar zone, and later that of granule cell precursors in the
external granular layer.3,4 During formation of the limb
skeleton, SHH is required for the survival and expansion
of distal chondrogenic progenitor cells and for specifica-
tion of digit identities along the anterior-posterior axis.5
In vertebrates, SHH signaling is critically mediated by
the primary cilium, a microtubule-based organelle pro-
truding from the surface of nearly all cell types. Many
components of the SHH pathway are variably localized
within the cilia at different steps of pathway activa-
tion,6,7 and the malfunctioning of many ciliary genes is
known to impair SHH signaling.8–11 When the pathway
is inactive, the SHH receptor PTCH1 inhibits the ciliary
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localization and activation of the seven-pass membrane
protein SMO. In this condition, the effectors GLI2 and
GLI3 are restrained to the cytoplasm, where they form a
complex with Suppressor of Fused (SUFU), the main nega-
tive regulator of the pathway, and undergo partial protea-
somal-mediated proteolysis. This removes the C terminus
activation domain and generates the transcriptional
repressor forms GLI3R and, to a lesser extent, GLI2R.
Upon SHH binding, PTCH1 exits the cilium relieving
SMO inhibition. This promotes the progressive dissocia-
tion of SUFU from GLI2-3 proteins, their translocation
to the cilium tip, and inhibition of their cleavage, leading
to the formation of the transcriptional activators GLI2A
and GLI3A. In turn, these translocate to the nucleus to
activate the expression of several target genes, such as
GLI1 (MIM: 165220), BCL2 (MIM: 151430), and PTCH1
itself (MIM: 601309).12–14 As GLI1 lacks the N-terminal
repression domain, it works exclusively as a transcrip-
tional activator whose activity is also constrained by
SUFU, and appears to function as part of a positive feed-
back loop to reinforce the transcriptional output of SHH
signaling.15
Ciliopathies such as Joubert syndrome (JS [MIM:
213300]), acrocallosal syndrome (ACLS [MIM: 200990]),
and oral-facial-digital syndromes (MIM: 311200, 277170)
frequently present with congenital defects of the CNS
(e.g., cerebellar vermis hypoplasia, ‘‘molar tooth sign’’
[MTS], defects of the corpus callosum, polymicrogyria),
midline facial anomalies, and polydactyly, which are at
least partially attributed to altered SHH signaling.16–19
Similarly, heterozygous pathogenic variants directly
affecting several members of the SHH pathway, including
SHH itself (MIM: 600725), PTCH1, SMO (MIM: 601500),
GLI2 (MIM: 165230), or GLI3 (MIM: 165240), result in a
spectrum of autosomal-dominant developmental disor-
ders including holoprosencephaly (MIM: 142945),
schizencephaly with polymicrogyria (MIM: 269160),
Curry-Jones syndrome (CJS [MIM: 601707]), Greig cepha-
lopolysyndactyly syndrome (GCPS [MIM: 175700]), Pallis-
ter-Hall syndrome (MIM: 146510), and non-syndromic
polydactylies (MIM: 174200, 174700), that are variably
characterized by anomalies of the brain, midline face,
and/or limbs.20–23
An aberrant activity of the SHH pathway has also been
firmly associated with increased risk of developing cancer.
Germline heterozygous loss-of-function variants of either
PTCH1 or SUFU (MIM: 607035) may cause a complex con-
dition termed nevoid-basal-cell carcinoma syndrome
(Gorlin syndrome [MIM: 109400]), characterized by the
occurrence of several basal cell carcinomas and other can-
cers at a young age (<20 years), variably associated with
developmental and skeletal abnormalities.24,25 Moreover,
somatic variants of PTCH1 or SMO, and both germinal
and somatic variants of SUFU, have been found to predis-
pose to a variety of tumors, such as basal cell carcinoma,
meningioma, and cerebellar medulloblastoma (MIM:
605462, 607174, 155255).26–30
To date, germline recessive pathogenic variants of SUFU
have never been reported in human subjects, supporting
the essential role of SUFU in embryonic development.
Sufu knock-out mice display early embryonic lethality at
E9.5, with severe cranio-facial and neural closure defects
related to constitutive SHH pathway activation,31 similar
to that observed in Ptch1 mutants.32 Limb-specific condi-
tional deletion of Sufu results in polydactyly due to a block
in Gli3R processing,33,34 whereas mouse embryos with
conditional knock-out of Sufu in the mid-hindbrain show
altered morphology of the brainstem and cerebellum and
delayed differentiation and abnormal migration of most
cerebellar cell types.35
Here, we show that germline hypomorphic variants of
SUFU cause deregulation of the SHH pathway, resulting
in recessive stereotypical developmental defects of the
CNS and limbs which share peculiar features with both
SHH-related disorders and with ciliopathies such as JS.
Subjects, Material, and Methods
Subjects
Two large cohorts of subjects with neuroradiologically
confirmed JS or related cerebellar and brainstem defects
have been recruited at the IRCCS Santa Lucia Foundation
(Rome, Italy) and the University of California San Diego
(La Jolla, CA, United States). After obtaining written
informed consent from the affected subjects, parents, or
legal representatives, detailed clinical data and brain MRI
scans were obtained from the referring clinicians. Ethics
approvalhas beenobtainedby the local EthicsCommittees.
A cohort of 60 subjects with polymicrogyria (mostly
familial), negative for pathogenic variants in known genes,
was recruited through international collaborations.
Sequencing and Data Analysis
As part of ongoing research projects to identify the genetic
causes of brain ciliopathies and related conditions, 385
probands underwent whole-exome sequencing (WES)
and data were filtered as previously described.36,37 Subjects
found to carry pathogenic variants in known genes associ-
ated to ciliopathies or other congenital defects were
excluded from further studies. Pathogenicity and conser-
vation of identified variants were predicted using several
commonly used software (Table S1).
Bidirectional Sanger sequencingof the12exons andexon-
intron junctions of SUFU was performed using the Big Dye
Terminator chemistry (Applied Biosystems) in 60 probands
with polymicrogyria (mostly familial) and 100 healthy Ital-
ian control subjects.Moreover, SUFUwas included in a panel
of 120 known and candidate ciliopathy genes, for next gen-
eration sequencing-based targeted sequencing in a distinct
cohort of 346 probands with JS or related ciliopathies. Tar-
geted resequencing was performed on a Solid 5500xL
platform using the TargetSeq Custom Enrichment System
(ThermoFisher Scientific), as previously reported.36
The American Journal of Human Genetics 101, 552–563, October 5, 2017 553
In Silico Modeling of SUFU Missense Variants
Atomic coordinates of SUFU, in complex with GLI3, were
obtained from the Protein Data Bank38 (PDB: 4BLD) and
used for Molecular Dynamics (MD) simulations. The resi-
dues of the considered PDB file correspond to residues
28–285 and 345–480 of SUFU and residues 333–340 of
GLI3. The wild-type (WT) model was mutated in silico to
introduce p.Ile406Thr and p.His176Arg variants through
UCSC Chimera,39 yielding two further models. All three
models were embedded in boxes, extending up to 12 A˚,
and solvated using the TIP3P water model. The tleap
tool was also used to add counter ions in order to
neutralize the overall charge of the models. Each of
them was first energy-minimized and then equilibrated
for approximately 5 ns, by time steps of 1 fs. MD simula-
tions were performed three times on the three equilibrated
models for 200 ns by time steps of 2 fs, namely for
100 million steps. A 10 A˚ cutoff was used for non-bonded
short-range interactions, and long-range electrostatics
were treated with the particle-mesh Ewald method. Tem-
perature and pressure were maintained at 300 K and
101.3 kPa, respectively, using the Langevin dynamics
and piston method.
To analyze whether the protein was stable and close to
the experimental structure, the following measures were
calculated in WT and mutant proteins: (1) root-mean-
square deviation (RMSD), that measures the average
distance between all heavy atoms (in this case Ca atomic
coordinates) with respect to the X-ray structure; (2) root
mean square fluctuation (RMSF), measuring the deviation
over time between the positions of the Ca atomic coordi-
nates of each residue with respect to the X-ray structure;
and (3) dynamic cross correlation maps (DCCMs), that
allow investigation of the long-range interactions of
atoms. Peaks, corresponding to the Cij elements of the
map, are indicative of strong to moderate positive correla-
tion (red to green) or of strong tomoderate anti-correlation
(dark to light blue) between residues i-j. Per-residue RMSF,
hydrogen bonds, and secondary structure content were
determined with the Gromacs tools: g_rmsf, g_hbond and
do_dssp. 3D figures and motions were generated with
UCSC Chimera.
Cell Cultures and Treatments
Skin-derived primary fibroblasts from the two probands
(COR369 II:1 and MTI-2023 II:2, Figure S1) and from two
healthy control subjects were cultured in Dulbecco’s Modi-
fied Eagle Medium (DMEM) supplemented with inacti-
vated 20% fetal bovine serum (FBS), 2 mM L-glutamine,
and 1% penicillin/streptomycin, at 5% CO2 and 37
C.
Medium was replaced once a week until fibroblasts
expanded. Fibroblasts were detached with trypsin
(EuroClone) and replated for at least two passages. The
day before treatments, 3 3 105 fibroblasts were plated in
a 60mmdish. IMCD3 cells were grown in DMEM F12, sup-
plemented with inactivated 10% FBS, 2 mM L-glutamine,
and 1% penicillin/streptomycin, at 5% CO2 and 37
C.
Before treatments, cells were starved in DMEM with
0.1% FBS, 2 mM L-glutamine, and 1% penicillin/strepto-
mycin. Treatments were: 40 mM cycloheximide (Sigma-
Aldrich) for 24 hr, 50 mM MG132 (Sigma-Aldrich) for
6 hr, and 200 nM Smoothened Agonist (SAG) (Adipogen)
for 12 hr.
Expression Vectors and Transfection
The QuikChange II Site-Directed Mutagenesis kit (Applied
Biosystem) was used to insert either the p.Ile406Thr or the
p.His176Arg change in pSufu WT vector,40 according to
the manufacturer’s instructions. Constructs were trans-
formed by heat shock into DH5a competent bacteria,
grown in LB at 37C overnight and purified using the
EndoFree Plasmid Maxi kit (QIAGEN). Plasmids were
quantified by Nanodrop (ThermoFisher Scientific) and
verified by Sanger sequencing following standard proto-
col. Transfection experiments were performed using Lipo-
fectamine 2000 (Invitrogen) as recommended by the
supplier.
Cilia Formation and Immunofluorescence
Fibroblasts were plated onto coverslips and cultured in
DMEM with 20% FBS until 80% confluence. Thereafter,
they were serum starved for 24 hr in DMEM 0.1% FBS
to allow cilia formation. Cells were fixed in cold meth-
anol and coverslips were rinsed and blocked in PBS with
10% BSA prior to incubation with antibodies. For immu-
nofluorescence, we used acetylated-a-tubulin, g-tubulin,
HA or FLAG primary antibodies (Sigma-Aldrich) over-
night followed by incubation with goat anti-mouse Alexa
Fluor 555 and goat anti-rabbit Alexa Fluor 488. Nuclei
were stained with Hoechst (Invitrogen). Images were
analyzed at a confocal microscope (C2 Confocal Micro-
scopy System), either at 488 nm (green) or 561 nm
(red), by using a 603 1.4 NA Plan Apo objective (Nikon
Corporation) and captured by NIS Element AR 4.13.04
software.
Cell Extracts and Western Blot
Cells were lysed in RIPA buffer. Protein amount was deter-
mined by Bradford protein assay kit (BioRad). Lysates were
boiled for 5 min after dithiothreitol (DTT 200 mM, Sigma-
Aldrich) addition. Proteins were loaded on SDS-polyacryl-
amide gels and transferred to nitrocellulose by standard
procedures.
Antibodies were used against the following proteins or
peptides: SUFU (Cell Signaling), GAPDH and HA (Sigma-
Aldrich), GLI3 and GLI1 (R&D). All the antibodies were
used according to the manufacturer’s instructions. Densi-
tometric analyses were performed with the ImageQuant
software.
Co-immunoprecipitation
Transfected IMCD3 cells were lysed in RIPA 13 buffer
containing 1% protease inhibitor and 1% phosphatase in-
hibitor (ThermoFisher Scientific) and 500 mg of total lysate
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were used for immunoprecipitation. The lysate was incu-
bated with beads, directly conjugated with HA antibody
(Red anti-HA beads, Sigma-Aldrich), overnight at 4C.
The day after, the immunocomplexes were washed three
times in lysis buffer, resuspended in 25 mL of sample buffer,
and finally processed in western blotting (WB).
Real-Time Quantitative PCR
Total RNA was extracted from fibroblasts with the High
Pure RNA Isolation Kit (Roche). A total amount of 500 ng
RNA was reverse transcribed using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems), ac-
cording to the manufacturer’s instructions. After cDNA
synthesis, samples were loaded in duplicate into a
384-well Custom TaqMan Array Card (ThermoFisher
Scientific) and run on an ABI Prism 7900HT sequence
detection system (Applied Biosystems). This whole experi-
ment was run in triplicate. b-actin was used as internal
control to normalize the data on each card, as well as
between cards.
Figure 1. Clinical and Neuroimaging
Features of Subjects Harboring SUFU
Homozygous Missense Variants
(A–D) Photographs of the four children
from families COR369 (A, B) and MTI-
2023 (C, D). Note hypertelorism, frontal
bossing, and broad, depressed nasal bridge.
(E and F) Bilateral hand post-axial polydac-
tyly (E) and plantar dyskeratotic pits (F) in
the male sibling from family COR369.
(G) Right hand post-axial polydactyly in
the male sibling from family MTI-2023.
(H–O) Brain MRI of affected girl (H–K) and
boy (L–O) from family COR369. Note mild
vermis hypoplasia (H, L) and elongated,
thickened, and horizontally orientated su-
perior cerebellar peduncles consistent
withmild MTS (I, M), associated with bilat-
eral polymicrogyria mainly involving the
right perisylvian regions (arrows in J, K,
N, O). Also note the megacisterna magna
in the sagittal image of the girl (H).
(P–S) Brain MRI in the proband from fam-
ily MTI-2023. Note vermis hypoplasia,
megacisterna magna (P, Q), dysplastic
foliar abnormalities (curved arrows in R),
deep interpeduncular fossa, and thickened
horizontally orientated superior cerebellar
peduncles (mild MTS, Q).
In all subjects, mild lateral ventricular
enlargement and shrunken white matter
in the supratentorial posterior regions are
visible (K, N, O, S). MRI of the fourth child
were not available for publication.
Statistical Analysis
qRT-PCR data are expressed as mean
5 standard error (SE). Data analyses
and statistical evaluations were
performed using the computing envi-
ronment R (v.3.4.0). A two-tailed
Student’s t test was applied to identify
genes that were differentially expressed between two
groups and a value of p < 0.05 was deemed statistically
significant.
Results
Identification of SUFU Recessive Missense Variants
In our combined cohorts of subjects with JS and related
disorders, we identified four children from two unrelated
families (COR369 from Italy and MTI-2023 from Egypt)
with similar clinical presentation, who carried homozy-
gousmissense variants of SUFU (Figure S1). All subjects pre-
sented peculiar facial dysmorphisms (hypertelorism, broad
and depressed nasal bridge, frontal bossing), oculomotor
apraxia, developmental delay with mild intellectual
impairment, gait ataxia, and dysarthria. Three of them
had post-axial polydactyly and two had global macrosomia
withmacrocephaly. One child also showed a few small dys-
keratotic pits on the foot soles (Figures 1A–1G). There were
no other signs of systemic involvement, except for mild
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retinopathy in one sibling from family COR369. Brain
imaging showed cerebellar vermis hypoplasia with elon-
gated superior cerebellar peduncles and deepened interpe-
duncular fossa (mild MTS) in all children; in addition, the
two siblings from family COR369 had bilateral polymicro-
gyria mainly involving the perisylvian regions (Figures
1H–1S). A detailed description of the four affected children
is provided in Supplemental Note and Table S2.
In family COR369, two distinct homozygous missense
variants survived the steps of stringent filtering of WES
data, Sanger validation, and segregation analysis: hg19:10:
g.104377106T>C; c.1217T>C (p.Ile406Thr) in SUFU
(GenBank: NM_016169.3) and hg19:10: g.85973943A>T;
c.2146A>T (p.Thr716Ser) in CDHR1 (MIM: 609502;
GenBank: NM_033100) (Figure S2). Both variants are
absent from all public databases (dbSNP, EVS, gnomAD,
Human Longevity Database) and from in-house WES
databases consisting of more than 6,000 samples and are
unanimously predicted to be deleterious (Table S1). Only
one individual in the gnomAD database carried a heterozy-
gous missense variant affecting the same SUFU residue but
resulting in a different amino acid change (c.1218C>G
[p.Ile406Met]). CDHR1 (also termed PCDH21) is expressed
only in the outer nuclear layer of the retina and encodes
for protocadherin 21. Recessive variants of this gene are
known to cause a form of cone-rod dystrophy with onset
in the late second decade of life (MIM: 613660).
In familyMTI-2023, only thehg38:10: g.102592654A>G;
c.527A>G (p.His176Arg) variant in SUFU survived bio-
informatic filtering of WES data and segregation analysis
(Figure S2). This variant is absent from public databases
and our in-house dataset, which includes sequencing data
frommore than3,000Egyptian individuals, and ispredicted
to have a deleterious impact on the protein function
(Table S1).
An additional 12/731 (1.6%) probands carried heterozy-
gous rare variants of SUFU (Table S3), while no pathogenic
variants were detected in 60 subjects with isolated polymi-
crogyria or in 100 Italian control subjects.
Dynamic Properties of Mutant SUFU Proteins
The SUFU protein alternates between ‘‘open’’ and ‘‘closed’’
conformations. The closed form is stabilized by the binding
with GLI proteins, whereas the open state is caused by the
dissociation from GLI. Changes of critical residues on the
interface between SUFU andGLI proteinsmay disrupt their
complex and prevent SUFU from repressing GLI-mediated
transcription. To assess the pathogenic effect of the identi-
fied missense variants, we first investigated their structural
and dynamic impact on the SUFU protein (Figure 2A) by
means of a series of molecular dynamics tools.
SUFU WT reached a stable state already after 60 ns of
simulation, recording an RMSD of 0.3 nm. Conversely,
both SUFU mutants exhibited RMSD levels around
0.5 nm, after a longer stabilization stage of 150 ns
(Figure 2B). Moreover, mutants turned out to be more
flexible than WT. The loop made by the amino acid resi-
dues 354–385 was themost fluctuating region in all models
but reached very high values (1.4 nm) for SUFUp.Ile406Thr.
SUFUp.His176Arg also showed altered RMSF values compared
to WT, mainly affecting the region nearby the mutation,
which is known to participate in the formation of the
GLI3-binding pocket (Figure 2C).
DCCMs of both mutants versus WT showed a dramatic
change in the protein dynamics. In the WT model, the
linker domain moved in a highly anti-correlated way
with both the C-terminal and the N-terminal regions of
the core domain. The SUFUp.Ile406Thr mutant acquired
intra-domain anti-correlated motions in the C-terminal
domain and in the N-terminal domain but completely
changed the inter-domain correlated and anti-correlated
motions. SUFUp.His176Arg exhibited a similar trend about
the C-terminal domain, but it lost anymotion between res-
idues in the N-terminal domain. Overall, both mutants
displayed random movements of the residues within the
C-terminal domain and loss of the native enveloping
movement of the binding site around GLI3 protein
(Figure 2D, Movie S1).
To confirm the observed major perturbation of SUFU-
GLI3 complex activity, we analyzed the modification of
hydrogen bonds (h-bonds) between residues that consti-
tute the SUFU-GLI3 binding site, as well as the size of the
binding pocket. The GLI3 peptide, indeed, fits snugly
into a narrow channel with the histidine from the SYGH
motif, protruding into a binding pocket where it forms
hydrogen-bonding interactions with specific amino
acids.41 During 200 ns simulation time, the WT protein
repeatedly changed the size of the binding site and the
number of h-bonds depending on the alternative open or
closed conformations, while both mutants kept an almost
stable distance between amino acids constituting the bind-
ing site and an almost constant number of h-bonds with
GLI3 (Figures 2E and 2F). Overall, these findings suggest
that both mutants hamper significantly the functional
open/close states of the protein to different extents.
SUFU Missense Variants Reduce Protein Stability
It is well established that activation of the SHH pathway in
mammals is mediated by primary cilia, and that patho-
genic variants in KIF7, which is a key inhibitor of the
pathway, cause a spectrum of phenotypes overlapping
with the typical features of JS.19,42 We then tested whether
the identified SUFUmissense variants could affect ciliogen-
esis but did not observe any abnormality in ciliary length
or morphology in starved mutant fibroblasts compared
to controls (Figure S3).
To evaluate whether SUFU variants could impact protein
stability, IMCD3 cells were transfected with HA-tagged
SUFU WT, SUFUp.Ile406Thr, or SUFUp.His176Arg for 24, 48,
and 72 hr and processed by WB. Mutant SUFU protein
levels were significantly lower than WT already at 24 hr
and decreased rapidly, with SUFUp.Ile406Thr almost disap-
pearing at 72 hr after transfection (Figure 3A). Moreover,
confocal microscopy analysis showed an abnormal
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subcellular localization of SUFUp.Ile406Thr, which tended to
form intracytoplasmic aggregates, while SUFU WT and
SUFUp.His176Arg had uniform cytoplasmic and nuclear
localization (Figure S4). Similar results were obtained in
HeLa cells (data not shown).
SUFU protein levels are regulated within the cell mainly
by degradation through the ubiquitin-proteasome system
(UPS).43 To test whether the observed reduction in SUFU
levels was due to increased UPS-mediated degradation,
transfected IMCD3 cells were treated with the proteasomal
inhibitor MG132 for 6 hr and analyzed by WB. Proteaso-
mal blockage induced the accumulation of both WT and
mutant SUFU proteins, confirming that mutant proteins
are processed through the UPS (Figure S5). To exclude
that the observed reduction of mutant SUFU was due to
impaired protein synthesis, we treated control and mutant
fibroblasts with cycloheximide, to block de novo synthesis
of SUFU. Interestingly, the levels of bothmutant SUFU pro-
teins were slightly but significantly lower than controls
even in basal conditions, and showed a more marked
decrease after 24 hr treatment (Figure 3B). These findings
support the observation that both missense variants in-
crease the rate of SUFU degradation within cells.
SUFU Missense Variants Impair the Binding with GLI3
and Its Proteolytic Cleavage
Next, we focused on the interaction between SUFU and
GLI3, since it is known that the major contribution to
Figure 2. Analysis of MD Simulations of WT and Mutant SUFU Proteins
(A) 3D structure of SUFU-GLI complex. The N-terminal (28–262), C-terminal (266–285; 345–480), and linked (263–265) domains are
colored green, yellow, and gray, respectively, while the GLI3 protein is colored in red. p.Ile406Thr is highlighted in blue and p.His176Arg
in orange.
(B) RMSD of all heavy atoms of SUFU.
(C) RMSF of SUFU residues during simulations.
(D) Covariancematrix for SUFUWT (top), SUFUp.Ile406Thr (center), and SUFUp.His176Arg (bottom). Perfect direct or inverse correlations are
highlighted in red or violet, respectively.
(E) Distances between amino acids forming the binding site for GLI3.
(F) H-bonds established during simulation between the residues forming the ligand binding pocket and GLI3.
In (B)–(F) graphs, SUFU WT is colored in black, SUFUp.Ile406Thr in red, and SUFUp.His176Arg in green.
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the repressor forms of GLI comes from GLI3. Indeed,
cleaved GLI3R suppresses SHH target genes when
the pathway is inactive, while activated GLI2 triggers
target gene expression upon stimulation of the
pathway.15
To examine whether the identified missense variants
could affect SUFU-GLI3 binding, as suggested by MD
simulations, co-immunoprecipitation experiments were
performed on total protein extracts of IMCD3 cells trans-
fected with either HA-tagged SUFU WT, SUFUp.Ile406Thr, or
SUFUp.His176Arg. The binding of unprocessed GLI3 was
significantly higher with SUFU WT than with either of
the two mutant proteins, suggesting that both missense
variants impaired the ability of SUFU to bind GLI3
(Figure 4A). To further confirm this finding, we measured
by WB analysis the levels of GLI3 full length and GLI3R
in control or mutant fibroblasts cultured in the presence
or absence of SAG, a SMO agonist able to activate the
SHH pathway. As expected, in control fibroblasts, both
GLI3 full length and GLI3R levels decreased after SAG
treatment.44 In mutant cells, GLI3 full length and
GLI3R levels were already significantly lower than control
in untreated conditions, with a further slight decrease
Figure 3. SUFUMissense Variants Reduce
Protein Stability
(A) IMCD3 cells transfected with HA-
tagged SUFU WT, SUFUp.Ile406Thr, and
SUFUp.His176Arg for 24, 48, and 72 hr show
a more rapid decrease of mutant SUFU
protein levels compared to WT (quantified
by densitometry in the corresponding
graphs).
(B) Control and mutant fibroblasts were
treated with cycloheximide for 24 hr.
Mutant cells show significantly lower
levels of SUFU even in basal conditions,
with a further more marked decrease after
treatment.
Results are representative of at least three
independent experiments. Graphs repre-
sent means5 standard errors. *p < 0.05.
upon SAG stimulation (Figures 4B
and S6). Taken together, these results
suggest that the identified missense
variants reduce the binding affinity
of SUFU to GLI3, resulting in
impaired repression of the pathway
in basal conditions.
To test whether mutant SUFU pro-
teins also showed impaired binding
to GLI1, an effector of the pathway
lacking repressor properties,41 we per-
formed immunofluorescence and
co-immunoprecipitation experiments
in IMCD3 cells co-transfected with
plasmids expressing either WT or
mutant SUFU and GLI1. However,
we did not observe any notable differ-
ence in co-localization of the two proteins, nor in SUFU-
GLI1 binding (Figure S7).
SUFU Missense Variants Impair Repression of the SHH
Pathway
In light of the previous results, we sought to assess whether
the SHH pathway was deregulated in the presence of
mutant SUFU. To this aim, we evaluated by quantitative
real-time PCR in control andmutant fibroblasts the expres-
sion levels of 14 genes, including several target genes of the
SHH pathway and representative genes of other develop-
mental pathways such as BMP, canonical Wnt, and non-
canonical Wnt/planar cell polarity (PCP) pathways.
Interestingly, the basal expression levels of the key SHH-
target genes BCL2, GLI1, and PTCH1 were significantly
higher in both mutant fibroblasts compared to control,
with a limited further increase upon SAG stimulation.
Conversely, mutant cells showed markedly lower basal
expression levels of VANGL2 (involved in the PCP
pathway), which were only minimally perturbed after
SAG treatment (Figure 5). These altered expression levels
could be partially rescued by overexpression of SUFU WT
in mutant fibroblasts (data not shown). Other genes
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appeared to be deregulated without reaching statistical
significance, or remained unperturbed (Table S4). These
findings confirm the previous observations that the identi-
fied missense variants impair the ability of SUFU to consti-
tutively repress the SHH pathway, which results in deregu-
lation of target gene expression especially in unstimulated
conditions.
Discussion
Herewe report the occurrence of homozygousmissense var-
iants in SUFU in four children from two consanguineous,
unrelated families presentingwithmild features of JS associ-
ated with peculiar cranio-facial anomalies and polydactyly.
Functional studies on fibroblasts and cell lines showed
that the mutant proteins were less stable and more rapidly
degraded than SUFU WT and had impaired ability to bind
GLI3 and promote its cleavage into the repressor form
GLI3R, while they maintained unaltered ability to bind
GLI1. These findings suggest that both variants are hypo-
morphic alleles, resulting only in a partial loss of the normal
gene function. This is in line with the previous observations
that complete Sufu knock-out is lethal in mouse embryos31
and thathuman SUFU is extremely intolerant to loss of func-
tion and generally intolerant to variation. In fact, homozy-
gous loss-of-function variants were never observed in more
than 138,000 individuals from the gnomAD database (pLI
score ¼ 1),45 and even synonymous and missense variants
Figure 4. SUFU Missense Variants Impair
Binding to GLI3
(A) Co-immunoprecipitation experiments
in IMCD3 cells transfected with either
HA-tagged SUFU WT, SUFUp.Ile406Thr, or
SUFUp.His176Arg, showing reduced binding
of GLI3 to mutant SUFU.
(B) GLI3 full length and GLI3R levels in
mutant fibroblasts are significantly lower
than in controls in basal conditions, with
a further decrease after 24 hr SAG stimula-
tion.
Results are representative of at least four
independent experiments. Graphs repre-
sent means5 standard errors. *p < 0.05.
were observed at significantly lower
frequency than expected (positive
Z scores of 1.82 and 2.54, respectively)
and nearly always in the heterozygous
state. Of note, the Geno2MP
database reports the occurrence of a
rare, potentially harmful homozygous
missensevariant inSUFU (p.Ala425Val,
CADD score 18.38) in a single subject
with reported cerebellar anomalies.
Although we were not able to get in
touch with the referring clinician, this
individual may represent yet another
case of SUFU recessive hypomorphic mutations giving rise
to a neurodevelopmental phenotype.
We also identified heterozygous rare variants of SUFU in
12 children with JS, none of which had developed any tu-
mors or signs of Gorlin syndrome. Eight variants were
missense changes largely predicted as benign, and in fact
biallelic pathogenic mutations in a well-established JS-
associated gene were detected in five carriers (Table S3).
The other four SUFU variants included a splice site variant
and three loss-of-function variants predicted to result in
SUFU haploinsufficiency. Three variants had been in-
herited by a healthy parent, while one appeared to have
arisen de novo. Interestingly, the frequency of SUFU hetero-
zygous loss-of-function variants among JS-affected sub-
jects (3/761) is markedly higher than the frequency
reported in gnomAD database (4/138,629, p < 216), sug-
gesting a potential role of SUFU haploinsufficiency in the
determination of the JS phenotype. On the other hand,
SUFU heterozygous loss-of-function variants have been
described in several young children diagnosed withmedul-
loblastoma, often inherited from a healthy parent.27While
macrocephaly and/or hypertelorism have been reported in
a subset of these case subjects, we could not find any
mention of developmental delay, ataxia, or intellectual
impairment, nor of the presence of congenital cerebellar
or brainstemmalformations that would suggest a diagnosis
of JS in any of these published case subjects. Thus, at pre-
sent, the significance of SUFU heterozygous variants in
the context of JS remains to be determined.
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Recently, Makino and collaborators generated Sufu
knock-in mice homozygous for the missense variant
p.Thr396Ile, which lies only ten amino acids away from
the homozygous variant p.Ile406Thr identified in family
COR369. These animals died later than knock-out mice
(at E14–E18) and showed a spectrum of developmental
anomalies including cranio-facial defects and polydactyly,
which were similar to those observed in mice lacking Gli3,
but not in those lacking Gli1 or Gli2. In line with this, a
functional characterization of SufuT396I/T396I mice showed
reduced stability of mutant Sufu and significantly reduced
levels of Gli3 full length and Gli3R, without quantitatively
affecting the levels of either Gli1 or Gli2.46 Intriguingly,
the clinical and functional anomalies of this knock-in
model closely resemble those of the affected children
described here and support our observation that recessive
hypomorphic variants in SUFU may induce deregulation
of the SHH pathway through two distinct mechanisms:
on one hand by reducing SUFU half-life within cells, on
the other hand by selectively impairing its interaction
with GLI3 and the subsequent formation of GLI3R.
In line with these observations and with the notion that
GLI3R is the principal repressor of SHH signaling,15 we
found in basal conditions a significant overexpression of
three key target genes (namely BCL2, GLI1, and PTCH1)
in mutant fibroblasts compared to controls. Upon SAG-
induced activation of the SHH pathway, which is mainly
mediated by GLI1 and GLI2A, the expression levels of
these genes further increased, as expected. Interestingly,
in both mutant fibroblasts we also observed a marked
downregulation of the expression levels of VANGL2, a
gene encoding for a protein of the non-canonical Wnt/
PCP pathway, which also requires primary cilia for its acti-
vation.47 In particular, VANGL2 has been implicated in
neuronal migration and post-crossing commissural axonal
guidance;48,49 our observations in mutant fibroblasts sug-
gest that SUFU might play an important role in sustaining
VANGL2 expression levels and that alterations of the PCP
pathway may contribute to the developmental defects in
individuals carrying SUFU hypomorphic variants.
Further support to the link between the identified SUFU
variants and a deregulation of SHH signaling comes from
the observed phenotype, which is mainly characterized
by (1) typical cranio-facial dysmorphisms (hypertelorism,
depressed nasal bridge, frontal bossing, macrocephaly);
(2) developmental delay, mild intellectual impairment,
ataxia, and ocular-motor apraxia; (3) cerebellar vermis
hypoplasia with dysplastic foliar pattern and mildly elon-
gated superior cerebellar peduncles (mild MTS); and (4)
postaxial polydactyly. This clinical presentation shares fea-
tures both with ciliopathies such as JS and with syndromes
characterized by impaired repression of the SHH pathway.
JS is typically diagnosed by the presence of the MTS, and
more than 30 genes associated to JS have been identified to
date.50 Among these, recessive pathogenic variants in KIF7
were found to cause a spectrum of anomalies ranging from
pure JS to ACLS, which is characterized by the MTS, corpus
callosum agenesis, pre- and post-axial polydactyly, and
similar cranio-facial abnormalities as shown by SUFU-
mutated individuals. Interestingly, KIF7 is a ciliary protein
that promotes the localization and appropriate regulation
of SUFU and GLI proteins at the ciliary tip.19,51 In the
absence of functional KIF7, the ciliary tip compartment
becomes disorganized, leading to the formation of ectopic
tip-like compartments where GLI-SUFU complexes localize
and are inappropriately activated even in the absence of
SHH ligand.52
The same constellation of cranio-facial abnormalities
along with developmental delay and polysyndactyly is
detected in GCPS, in which heterozygous GLI3 variants
result in reduced levels of Gli3R.21 Recently, a recurrent
mosaic heterozygous nonsynonymous variant in SMO
(c.1234C>T [p.Leu412Phe]) causing overactivation of the
SHH pathway was found to cause CJS, a multisystem disor-
der characterized by patchy skin lesions, unicoronal
craniosynostosis, iris colobomas, microphthalmia, and in-
testinal malrotation. Of note, subjects with CJS also
present similar cranio-facial dysmorphisms and polysyn-
dactyly, as well as a spectrum of cerebral malformations
including mild cerebellar hypoplasia, corpus callosum
abnormalities, and polymicrogyria.23
Moreover, a proportion of subjects with Gorlin syn-
drome, caused by heterozygous loss-of-function variants
of either PTCH1 or SUFU, variably exhibit macrocephaly,
Figure 5. The SHH Pathway Is Deregulated in Mutant Fibroblasts
Histograms show the expression levels of four target genes that in basal conditions are either significantly overexpressed (BCL2, GLI1,
and PTCH1) or under-expressed (VANGL2) in fibroblasts from the two probands compared to control subjects. Results are representative
of three independent experiments. Graphs represent means5 standard errors. *p < 0.05.
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hypertelorism, depressed nasal bridge, post-axial polydac-
tyly, as well as macrosomia and dyskeratotic plantar pits
(present in family COR369).24 These observations suggest
that these peculiar cranio-facial and digit anomalies are
strictly related to abnormal activation of the SHH pathway,
caused either by reduced levels (or functioning) of
repressor proteins or by the constitutive activation of pro-
teins that transduce SHH signaling. Conversely, genetic
changes impairing activation of the SHH pathway, such
as heterozygous variants of SHH or GLI2, are consistently
associated with opposite cranio-facial dysmorphisms
such as microcephaly, hypotelorism, microphthalmia,
midface hypoplasia, and cleft lip/palate, that variably asso-
ciate with forebrain cleavage anomalies (defining the
holoprosencephaly spectrum) and digital number abnor-
malities.15,20
None of the other features typical of Gorlin syndrome
(keratocystic odontogenic tumors, ribs and spine abnor-
malities, calcification of the falx cerebri) were present in
the four children carrying recessive SUFU variants, nor
had they developed any cancer. This could be related to
the fact that these clinical features may only manifest in
the presence of SUFU haploinsufficiency (and often in
conjunction with a somatic ‘‘second hit’’ in cancer cells),
while SUFU proteins carrying hypomorphic variants were
defective in only selected properties. However, all children
are still young, and a longer follow-up will be needed to
definitely exclude the occurrence of tumors.
The observed phenotypic variability observed in carriers
of SUFU-recessive variants is not surprising, as it is also
observed in most ciliopathies as well as in other defects
of the SHH pathway.20,22 In particular, the observed
different impact of the two missense variants on SUFU
subcellular distribution and degradation, GLI3 cleavage,
and expression of target genes may enlighten some differ-
ences between the two families, such as the occurrence, in
family COR369, of more severe polydactyly and of
asymmetric polymicrogyria, prevalent in the perisylvian
regions.
Polymicrogyria has been occasionally reported in sub-
jects with JS caused by pathogenic variants in distinct
ciliary genes,18,53,54 as well as in a boy with schizencephaly
and partial absence of the corpus callosum carrying a SHH
heterozygous variant.55 Moreover, two families with iso-
lated diffuse polymicrogyria were found to carry recessive
pathogenic variants in RTTN encoding Rotatin, a centro-
some-associated protein essential for maintaining normal
ciliary structure and functioning. Interestingly, an expres-
sion study in RTTNmutant fibroblasts showed a significant
deregulation of several genes involved in the SHH and
WNT pathways, similarly to what we observed in SUFU
mutant cells.56 Taken together, these observations support
the finding that polymicrogyria can be part of the spec-
trum of brain developmental anomalies associated with
deregulation of SHH signaling.
Besides SUFU p.Ile406Thr, the two affected siblings in
family COR369 also shared the homozygous variant
p.Thr716Ser in CDHR1. Pathogenic variants of this gene
are known to cause an autosomal-recessive form of cone-
rod dystrophy with onset in the late second decade of
life, thus at a later age than that of both siblings, who
had preserved visual acuity and normal fundoscopy.
However, it is worth noting that an electroretinogram
performed in the brother showed signs of underlying reti-
nopathy, requiring further investigation and follow-up.
In conclusion, we report that germline recessive hypo-
morphic variants in SUFU may alter its stability and
function as repressor of the SHH pathway, giving rise to
a peculiar spectrum of developmental defects sharing
features of ciliopathies such as JS and of SHH-related
disorders. The occurrence of specific cranio-facial and
digit abnormalities should represent red flags implicating
an underlying defect of genes involved in the SHH
pathway.
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